share_log

Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $11

Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $11

古根海姆维持对Passage Bio的买入,将目标股价下调至11美元
Benzinga Real-time News ·  2022/11/11 08:44

Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $13 to $11.

古根海姆分析师黛布吉特·查托帕迪亚维持Passage Bio(纳斯达克股票代码:PASG)的买入,并将目标股价从13美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发